Bora Pharmaceuticals (保瑞藥業) announced on May 18, 2026, the signing of a landmark 10+2 year manufacturing agreement valued in the tens of billions of New Taiwan Dollars with a top 20 global biopharmaceutical corporation. Under this contract, Bora will leverage its global network to deliver one-stop CDMO solutions spanning development, manufacturing, packaging, and analytical services.

• Strategic Scaling & Revenue Impact: The newly acquired partner is projected to become one of Bora’s top three CDMO clients, driving the revenue contribution from Top 20 global pharmaceutical companies to over 40% of Bora's total portfolio.
• Maple Grove Asset Maximization: Bora's Maple Grove, Minnesota facility will serve as the primary site for initial production runs. Following this agreement, the site's pipeline has surged to 14 active molecular programs, with commercial-scale production molecules making up over half—a significant spike compared to late 2025. The facility specializes in large-scale oral solid dosage (OSD) forms.
• Capacity and Market Outlook: Upon completion of tech transfer, the initial phase of orders is anticipated to expand Bora’s annual consolidated manufacturing output by approximately 20%. This positions Bora to capitalize on the massive wave of onshoring and nearshoring sweeping the North American market, where over US$270 billion in domestic investment plans have been announced since 2025 amid the enforcement of the US Biosecure Act. Bora's multi-regional, multi-dosage network now spans 11 sites (5 in Taiwan, 1 in Canada, and 5 in the US).

Resource:保瑞新簽全球前20大藥廠客戶再告捷，Maple Grove廠率隊接大單